Compare Agilent Technologies Inc (A) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Agilent Technologies Inc trades at $128.71 (market cap $37.04B), while Norwegian Cruise Line Holdings Ltd trades at $18.39 (market cap $8.65B). The key difference: Agilent Technologies Inc is far larger — about 4.3× Norwegian Cruise Line Holdings Ltd's market cap, and Agilent Technologies Inc pays a 0.78% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| A | NCLH | |
|---|---|---|
Market Cap | $37.04B | $8.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $157.20 | $26.94 |
52-Week Low | $110.24 | $14.79 |
Enterprise Value | $38.59B | $23.61B |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
NCLH trades at $18.83, down 4.8% on the day, reflecting near-term pressure amid a bearish technical signal. The company has demonstrated consistent earnings beats, with Q1 2026 EPS of $0.23 exceeding the $0.15 estimate. Fundamentals show a P/E of 15.53 and a net income margin of 5.66%, while recent news highlights new executive appointments and future cruise itineraries. The stock is trading below the consensus analyst price target of $22.00.
The outlook is mixed; strong earnings performance and a favorable valuation offer upside potential, but high debt levels and a bearish technical trend present significant risks. The stock's performance is closely tied to travel demand and macroeconomic factors affecting the cruise industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
